Clinical trials: Hepatic Decompensation
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Cirrhosis
"Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
Further decompensation (FD) in cirrhosis represents a prognostic stage associated with an even higher mortality than that associated with the first decompensation.
- Trial name
- Ant-TIPS (NCT07889726)
- Testing
- TIPS, Standard of Care (SOC)
- Where
- 8 sites in France
- Volunteers
- 266 people
- Sponsor
- University Hospital, Toulouse
Liver Cirrhoses, Hepatocellular Carcinoma (HCC)
A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease.
- Conditions
- Liver Cirrhoses, Hepatocellular Carcinoma (HCC), Sarcopenia in Liver Cirrhosis, Portal Hypertension Related to Cirrhosis
- Trial name
- DETECT-HCC (NCT07291141)
- Where
- Sweden
- Volunteers
- 600 people
- Sponsor
- Mattias Ekstedt
Hepatitis C, Chronic, Sustained Virological Response
Prediction of Liver-related Outcomes After HCV Cure
Objectives: To develop and validate a predictive model, applicable to daily practice, of liver complications emergence in hepatitis C virus (HCV)-infected patients and advanced fibrosis, who have achieved sustained viral response…
- Conditions
- Hepatitis C, Chronic, Sustained Virological Response, Direct-acting Antivirals, Hepatocellular Carcinoma
- Trial name
- NCT04460157
- Where
- Spain
- Volunteers
- 1,035 people
- Sponsor
- Hospital Universitario de Valme
Liver Decompensation, Hepatocellular Carcinoma
The Second Multicenter Hemophilia Cohort Study
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV).
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT00341705
- Where
- 48 sites in United States, Brazil and 6 more
- Volunteers
- 2,565 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as…
- Trial name
- NCT02455167
- Testing
- Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Cirrhosis
Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled.
- Trial name
- NCT01157845
- Testing
- BreathID (Methacetin breath test)
- Where
- 4 sites in United States, Israel
- Volunteers
- 165 people
- Sponsor
- Virginia Commonwealth University
Asymptomatic Cirrhosis, Clinically Significant Portal Hypertension
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
Decompensation of cirrhosis is a turning point in cirrhosis course, as associated with a marked decrease in life expectancy. Thus, prevention of decompensation is crucial.
- Trial name
- CARVECIR (NCT06263816)
- Testing
- Experimental group: Patients will be treated with carvedilol.
- Where
- 24 sites in France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Tours
Liver Cirrhosis
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
A feasibility trial called PROFIT has previously shown that FMT administered endoscopically into the jejunum in patients with cirrhosis is safe and feasible and have identified some potential mechanisms of action that warrant…
- Trial name
- PROMISE (NCT06461208)
- Testing
- Encapsulated FMT
- Where
- 23 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- King's College London
Liver Failure, Acute on Chronic, Liver Dysfunction
A Validation Cohort for ACLF Diagnosis and Prognosis
Acute on chronic liver failure (ACLF) is a distinct entity encompassing the acute deterioration of liver function, culminating in multiple organs failure and high short-term mortality.
- Trial name
- Ch-CANONIC-Val (NCT03641872)
- Testing
- Standary therapy
- Where
- 12 sites in China
- Volunteers
- 1,370 people
- Sponsor
- Hai Li
Liver Cirrhosis, Decompensated Cirrhosis of Liver
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the…
- Trial name
- PROSPECT (NCT06855056)
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 189 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- DPAILO-1 (NCT06344364)
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- 3 sites in Hong Kong, Spain
- Volunteers
- 1,241 people
- Sponsor
- PharmaNest, Inc
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard…
- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Trial name
- NCT06987968
- Testing
- VS-01 on top of SOC (Active Treatment Group), SOC
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Genfit
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Chronic Liver Disease and Cirrhosis, Chronic Liver Disease
hepatomiR cACLD Study
This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic…
- Conditions
- Chronic Liver Disease and Cirrhosis, Chronic Liver Disease, Portal Hypertension
- Trial name
- NCT06432582
- Testing
- hepatomiR
- Where
- Austria
- Volunteers
- 156 people
- Sponsor
- Karl Landsteiner University of Health Sciences
Liver Failure, Acute on Chronic
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Acute on chronic liver failure (ACLF) is a distinct entity encompassing the acute deterioration of liver function, culminating in multiple organs failure and high short-term mortality.
- Trial name
- Ch-CANONIC (NCT02457637)
- Testing
- Standary therapy
- Where
- 16 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Hai Li
Liver Dysfunction, Liver Insufficiency
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.
- Conditions
- Liver Dysfunction, Liver Insufficiency, Hepatic Failure, Myocardial Failure
- Trial name
- NCT03515980
- Testing
- BMS-986231
- Where
- 4 sites in Hungary, Poland
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HCC, Portal Vein Tumor Thrombosis
ISP-TACE Versus TACE for HCC With PVTT
For patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) remains modest.
- Trial name
- NCT03108248
- Testing
- ethiodized oil; doxorubicin;Gelfoam;, stent; idoine-125
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhongda Hospital
Cirrhotic Cardiomyopathy, Empagliflozin
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN.
- Conditions
- Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, Cirrhosis
- Trial name
- DICE (NCT07322237)
- Testing
- Empagliflozin + Carvedilol, Carvedilol
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.